Representing one of the world's leading pharmaceutical companies on patent infringement actions involving a blockbuster biological drug.
As an associate in Hogan Lovells intellectual property (IP) practice group, Ting Xiao focuses in patents and technology transfer. Ting has worked as a bio-medical scientist and has extensive laboratory research experience with both the renowned Chinese Academy of Sciences and the Ontario Cancer Institute in Canada. Ting's research has been published, including in Nature Methods. Ting has handled various contentious and non-contentious IP matters, including patent validity and infringement actions, anti-counterfeiting actions, IP procurement, patent and trade secret portfolio management, and cross-border IP transactions.
She also provides clients with overall strategic advice on IP protection and enforcement in China and internationally. Leveraging her life sciences background, Ting focuses on the pharmaceutical and biotechnology industries and is familiar with the regulatory regimes governing drugs and medical devices.
Advising a major Japanese pharmaceutical company on regulatory issues concerning biosimilars in China.
Representing one of the world's largest mobile device companies in defending a patent infringement action in China and applying to invalidate the asserted patent.
Advising a European seed company on IP licensing and sub-licensing transactions in China.
Acting for a major U.S. chemical company to review its competitor's patent position in China, and conducting patent infringement and validity assessment.
Advising a leading U.S. healthcare company on establishing R&D centres in China.